Song Dan, Gong Wei-Ping, Xiao Gui-Lin
Department of Dermatology, Zhoushan Hospital, Zhoushan City, Zhejiang Province, 316000, People's Republic of China.
Clin Cosmet Investig Dermatol. 2025 Apr 6;18:817-825. doi: 10.2147/CCID.S515200. eCollection 2025.
This study compares the efficacy and safety of Abrocitinib, a Janus kinase 1 (JAK1) inhibitor, and Dupilumab, an interleukin-4 and interleukin-13 inhibitor, in the treatment of Atopic dermatitis (AD).
A retrospective study was conducted on 136 patients with moderate to severe AD, treated with either Abrocitinib (n=60) or Dupilumab (n=76) from June 2022 to June 2024. Abrocitinib was administered at 100 mg/day orally, and Dupilumab at 300 mg subcutaneously every two weeks after a 600 mg loading dose. Primary outcome measures included serum immunoglobulin E (IgE) levels, eosinophil (Egb) counts, and clinical symptom improvement, assessed by the Eczema Area and Severity Index (EASI), Numeric Rating Scale (NRS) for pruritus, and Scoring Atopic Dermatitis (SCORAD). Quality of life was evaluated using the Dermatology Life Quality Index (DLQI), while emotional distress was assessed through the Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS). The incidence of adverse reactions was also recorded. Statistical significance was determined using -tests and Chi-square tests (p < 0.05).
Both treatments reduced IgE and eosinophil levels with no significant inter-group differences (p > 0.05). Abrocitinib was more effective in reducing pruritus, with a greater reduction in NRS scores (p < 0.05). EASI, SCORAD, DLQI, SAS and SDS improvements were similar, though Abrocitinib showed a greater reduction in anxiety (p = 0.011). The overall effective rate was higher in the Abrocitinib group (80.00%) compared to Dupilumab (69.73%) but not significantly (p = 0.174). Adverse reactions were minimal and comparable, with incidences of 8.33% for Abrocitinib and 9.21% for Dupilumab (p = 0.858).
Both Abrocitinib and Dupilumab are effective and well-tolerated treatments for atopic dermatitis. While their overall efficacy and safety profiles are comparable, Abrocitinib offers superior relief of pruritus. Both therapies represent valuable options in the management of moderate to severe atopic dermatitis.
本研究比较了Janus激酶1（JAK1）抑制剂阿布昔替尼和白细胞介素-4及白细胞介素-13抑制剂度普利尤单抗治疗特应性皮炎（AD）的疗效和安全性。
对2022年6月至2024年6月期间接受阿布昔替尼（n = 60）或度普利尤单抗（n = 76）治疗的136例中度至重度AD患者进行了一项回顾性研究。阿布昔替尼口服给药，剂量为100mg/天，度普利尤单抗在600mg负荷剂量后，每两周皮下注射300mg。主要观察指标包括血清免疫球蛋白E（IgE）水平、嗜酸性粒细胞（Egb）计数以及临床症状改善情况，通过湿疹面积和严重程度指数（EASI）、瘙痒数字评定量表（NRS）和特应性皮炎评分（SCORAD）进行评估。使用皮肤病生活质量指数（DLQI）评估生活质量，通过自评焦虑量表（SAS）和自评抑郁量表（SDS）评估情绪困扰。还记录了不良反应的发生率。采用t检验和卡方检验确定统计学显著性（p < 0.05）。
两种治疗方法均降低了IgE和嗜酸性粒细胞水平，组间差异无统计学意义（p > 0.05）。阿布昔替尼在减轻瘙痒方面更有效，NRS评分降低幅度更大（p < 0.05）。EASI、SCORAD、DLQI、SAS和SDS的改善情况相似，不过阿布昔替尼在减轻焦虑方面表现出更大的效果（p = 0.011）。阿布昔替尼组的总有效率（80.00%）高于度普利尤单抗组（69.73%），但差异无统计学意义（p = 0.174）。不良反应轻微且相当，阿布昔替尼的发生率为8.33%，度普利尤单抗为9.21%（p = 0.858）。
阿布昔替尼和度普利尤单抗都是治疗特应性皮炎的有效且耐受性良好的疗法。虽然它们的总体疗效和安全性相当，但阿布昔替尼在减轻瘙痒方面更具优势。两种疗法都是治疗中度至重度特应性皮炎的有价值选择。
